116 related articles for article (PubMed ID: 12451286)
1. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring.
Ciccolini J; Monjanel-Mouterde S; Bun SS; Blanc C; Duffaud F; Favre R; Durand A
Ther Drug Monit; 2002 Dec; 24(6):709-14. PubMed ID: 12451286
[TBL] [Abstract][Full Text] [Related]
2. Level of evidence for therapeutic drug monitoring for etoposide after oral administration.
Gerritsen-van Schieveen P; Royer B;
Fundam Clin Pharmacol; 2011 Jun; 25(3):277-82. PubMed ID: 20608987
[TBL] [Abstract][Full Text] [Related]
3. [Bayesian estimation of pharmacokinetic parameters of etoposide].
Evene E; Chatelut E; Tranchand B; Canal P; Lochon I; Iliadis A; Ardiet CJ
Bull Cancer; 1997 Jul; 84(7):699-703. PubMed ID: 9339195
[TBL] [Abstract][Full Text] [Related]
4. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.
Tranchand B; Amsellem C; Chatelut E; Freyer G; Iliadis A; Ligneau B; Trillet-Lenoir V; Canal P; Lochon I; Ardiet CJ
Cancer Chemother Pharmacol; 1999; 43(4):316-22. PubMed ID: 10071983
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion.
Wada I; Yokouchi M; Saitoh H; Takada M; Nakabayashi T; Mino K; Honma T; Takeda T; Hirano K
Int J Clin Pharmacol Ther; 1999 May; 37(5):254-9. PubMed ID: 10363625
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients.
Li D; Liu L
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):474-9. PubMed ID: 25828637
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
9. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents.
Kato Y; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2003 Feb; 45(1):74-9. PubMed ID: 12654074
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide.
Najar IA; Johri RK
J Biosci; 2014 Mar; 39(1):139-44. PubMed ID: 24499798
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the variability of etoposide pharmacokinetics in children.
Boos J; Real E; Schulze-Westhof ; Wolff J; Euting T; Jürgens H
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):495-7. PubMed ID: 1490803
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.
Fleischhack G; Reif S; Hasan C; Jaehde U; Hettmer S; Bode U
Br J Cancer; 2001 Jun; 84(11):1453-9. PubMed ID: 11384092
[TBL] [Abstract][Full Text] [Related]
16. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
Higa GM; Sarkar MA; DeVore RF
Pharmacotherapy; 1999 Jan; 19(1):101-7. PubMed ID: 9917083
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback.
Monjanel-Mouterde S; Ciccolini J; Bagarry D; Zonta-David M; Duffaud F; Favre R; Durand A
J Clin Pharm Ther; 2003 Apr; 28(2):109-16. PubMed ID: 12713607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]